Hypomyelination in autism-associated neuroligin-3 mutant mice impairs parvalbumin interneuron excitability, gamma oscillations, and sensory discrimination.

Publication date: Jul 10, 2025

Whether and how myelin plasticity, an emerging new form of brain plasticity, is involved in autism spectrum disorder (ASD) remains unknown. Here, we identify deficits in oligodendrocyte (OL) generation and myelination in the barrel cortex (BC) of the male NL3-R451C-KI mouse model of ASD. These mice also show impaired texture recognition, disrupted gamma neuronal oscillations, and reduced excitability and myelination level in the BC-PV interneuron. These abnormalities can be rescued by a promyelinating strategy and are recapitulated by genetic blockade of myelination in Myrf-cKO mice. Furthermore, OL progenitor-specific conditional NL3 knockout mice show similar deficits in BC-PV interneuron myelination and excitability, as well as neuronal oscillation and texture recognition, closely resembling the NL3-R451C-KI phenotype. Collectively, these results demonstrate that NL3 mutations commonly cause hypomyelination and reduced excitability in BC-PV interneurons, disrupting neuronal oscillation and contributing to ASD-like sensory dysfunction. Our finding reveals a mechanism underlying ASD and highlights OLs/myelin as potential therapeutic targets for ASD.

Open Access PDF

Concepts Keywords
Autism Animals
Genetic Autism Spectrum Disorder
Mice Autistic Disorder
Mutant Disease Models, Animal
Recapitulated Gamma Rhythm
Interneurons
Male
Membrane Proteins
Membrane Proteins
Mice
Mice, Knockout
Mutation
Myelin Sheath
Nerve Tissue Proteins
Nerve Tissue Proteins
neuroligin 3
Oligodendroglia
Parvalbumins
Parvalbumins
Somatosensory Cortex

Semantics

Type Source Name
disease MESH autism
disease MESH autism spectrum disorder
disease MESH abnormalities
drug DRUGBANK Guanosine
drug DRUGBANK L-Phenylalanine
disease MESH etiology
drug DRUGBANK Isoxaflutole
drug DRUGBANK Coenzyme M
disease MESH demyelinating diseases
disease MESH neurodegenerative diseases
pathway REACTOME Neurodegenerative Diseases
drug DRUGBANK Clemastine
drug DRUGBANK Trestolone
drug DRUGBANK Tamoxifen
drug DRUGBANK Tretamine
drug DRUGBANK Albendazole
disease MESH posture
drug DRUGBANK Esomeprazole
drug DRUGBANK Potassium Iodide
drug DRUGBANK Water
drug DRUGBANK Pentobarbital
drug DRUGBANK Dimethyl sulfoxide
drug DRUGBANK Broxuridine
drug DRUGBANK Flunarizine
drug DRUGBANK Sucrose
disease MESH dehydration
drug DRUGBANK Phosphate ion
drug DRUGBANK N-acetylsulfanilyl chloride
drug DRUGBANK Alkaline Phosphatase
drug DRUGBANK Ethanol
drug DRUGBANK Gold
drug DRUGBANK Medical air
drug DRUGBANK Aspartame
drug DRUGBANK Trypsin
pathway REACTOME Digestion
drug DRUGBANK Proline
drug DRUGBANK Edetic Acid
drug DRUGBANK Acetylcysteine
drug DRUGBANK L-Glutamine
drug DRUGBANK Dexamethasone
drug DRUGBANK Basic Fibroblast Growth Factor
drug DRUGBANK L-Lysine
drug DRUGBANK Isoflurane
drug DRUGBANK Pentaerythritol tetranitrate
drug DRUGBANK Ilex paraguariensis leaf
drug DRUGBANK Potassium Chloride
drug DRUGBANK Sodium bicarbonate
drug DRUGBANK Dextrose unspecified form
drug DRUGBANK Oxygen
drug DRUGBANK Carbon dioxide
drug DRUGBANK Phosphocreatine
drug DRUGBANK Lidocaine
drug DRUGBANK ATP
drug DRUGBANK Bicuculline
drug DRUGBANK Adenosine 5′-phosphosulfate
disease MESH Disease Models Animal

Original Article

(Visited 8 times, 1 visits today)

Leave a Comment

Your email address will not be published. Required fields are marked *